Nirsevimab doses for 2024-2025 RSV season can be reserved with new program
February 2nd 2024Nirsevimab was approved by the FDA on July 17, 2023, ahead of the traditional RSV season, though in October, the Centers for Disease Control and Prevention (CDC) recommended it be prioritized for the highest-risk infants amid limited availability.